

14-MAR-2002; 2002US-00097065.

QY	1	KKIAIVASVLPALPLCLIGDAAKQNDQEMGEFQAPAKNGKFLCPDQKXFPQSLDQIMFI	60
QY	1	KKIAIVASVLPALPLCLIGDAAKQNDQEMGEFQAPAKNGKFLCPDQKXFPQSLDQIMFI	60
Db	1	KKIAIVASVLPALPLCLIGDAAKQNDQEMGEFQAPAKNGKFLCPDQKXFPQSLDQIMFI	60
QY	61	NKCATCKMILLEKEAKSQCKARHLARAPATAPTEINCDDEPKSGERDGEICPDYVEAVCG	120
QY	61	NKCATCKMILLEKEAKSQCKARHLARAPATAPTEINCDDEPKSGERDGEICPDYVEAVCG	120
Db	61	NKCATCKMILLEKEAKSQCKARHLARAPATAPTEINCDDEPKSGERDGEICPDYVEAVCG	120
QY	121	TDGKTYDNRCAALCAENAKTGSQIGVKSSEGECKSSNPQDVCSAFRPVADGRLGCTREND	180
QY	121	TDGKTYDNRCAALCAENAKTGSQIGVKSSEGECKSSNPQDVCSAFRPVADGRLGCTREND	180
Db	121	TDGKTYDNRCAALCAENAKTGSQIGVKSSEGECKSSNPQDVCSAFRPVADGRLGCTREND	180
QY	181	PVLGRDQGTQANCAACALFLPKAEANAKREGRIIRNMEFDPCKEVYKQVRNRLPCT	240
QY	181	PVLGRDQGTQANCAACALFLPKAEANAKREGRIIRNMEFDPCKEVYKQVRNRLPCT	240
Db	181	PVLGRDQGTQANCAACALFLPKAEANAKREGRIIRNMEFDPCKEVYKQVRNRLPCT	240

QY 241 RESDPVAGPDGRMGKNCALCAEIFKRRFSEENSKTDONLGAKEKTVARBEIVKLCOSY 300  
 DB 241 RESDPVAGPDGRMGKNCALCAEIFKRRFSEENSKTDONLGAKEKTVARBEIVKLCOSY 300  
 QY 301 QONAKNGILFCTRENDDIRGPDGMHGNLCSMCQVYFAENEEKKAKARARRKREGKA 360  
 DB 301 QONAKNGILFCTRENDDIRGPDGMHGNLCSMCQVYFAENEEKKAKARARRKREGKA 360  
 QY 361 TSAVELCNEYRKYVRNGKLAICTRENDDIOGPDGVHNTSMCEVFPQAEERKKEGE 420  
 DB 361 TSAVELCNEYRKYVRNGKLAICTRENDDIOGPDGVHNTSMCEVFPQAEERKKEGE 420  
 QY 421 SRNRQKSTASFEELCSEYRKSRKNGRLFCTRENDDIOGPDGMHGNLCSMCQVFAEQE 480  
 DB 421 SRNRQKSTASFEELCSEYRKSRKNGRLFCTRENDDIOGPDGMHGNLCSMCQVFAEQE 480  
 QY 481 ERAPAKKRAAKAECSEFPDQVRNGTLCTRENDDIPRGDGMHGNLCSMCQVFAEQE 540  
 DB 481 ERAPAKKRAAKAECSEFPDQVRNGTLCTRENDDIPRGDGMHGNLCSMCQVFAEQE 540  
 QY 541 EEKNDKEBKXK 552  
 DB 541 KKKKK-KKKKK 551

## RESULT 9

AAV33001  
 ID AAV33001 standard; protein; 177 AA.

XX AC AAV33001;

DT 02-NOV-1999 (first entry)

DE Human serine protease inhibitor **VAKTI-1**-protein.

XX VAKTI-1; VAKTI-2; serine protease inhibitor; human; anti-inflammatory;  
 KM treatment; acute; chronic; cervical; inflammation; Bartholin gland;  
 KM vaginal; tonsillitis; pharyngitis; laryngitis; mucus secretion;  
 KM post-operative bleeding; fibrinolysis; pulmonary emphysema;  
 KM alpha 1-proteinase inhibitor.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers

FT Region /label= HF6479

FT Region /label= MEMC-1

FT Region /label= CHEP-1

FT Region /note="This region in the 5' to 3' orientation  
 represents the region designated CHEP-1 and in the 3' to  
 5' orientation represents the region designated CHEP-14"

FT Region /note="This region in the 3' to 5' orientation  
 represents the region designated CHEP-2"

FT Region /note="Region highlighted in the specification"

FT Region /note="Region highlighted in the specification"

PN WO9933974-A1.

PD 08-JUL-1999.

PP 23-DEC-1998; 98WO-EP008424.

PR 23-DEC-1997; 97DE-01057572.

PR 08-JAN-1998; 98DE-01000363.

XX (FORS/) FORSSMANN W.

PI Forssmann W, Maegert H, Staendker L, Kreutzmann P;

DR WPI; 1999-527189/44.  
 XX New inhibitors of serine protease useful for treating inflammation.  
 PT Claim 7; Fig 1; 41pp; German.  
 XX This invention describes the novel serine protease inhibitors VAKTI-1  
 CC and VAKTI-2 which have anti-inflammatory activity. The products of the  
 CC invention are used to treat acute or chronic cervical inflammation,  
 CC inflammation of the Bartholin glands and other vaginal regions,  
 CC tonsillitis, pharyngitis, laryngitis, inflammation involving excessive  
 CC secretion of mucus (including acute, emergency episodes), post-operative  
 CC bleeding as a result of excessive fibrinolysis, and for preventing  
 CC pulmonary emphysema caused by lack of alpha 1-proteinase inhibitor. The  
 CC nucleic acid products of the invention may also be used to raise  
 CC antibodies (Ab) and Ab or antisense nucleic acid directed against  
 CC sequences that encode the proteins of the invention. The proteins of the  
 CC invention can be used as diagnostic agents. This sequence represents  
 CC human VAKTI-1  
 XX

SO Sequence 177 AA;

Query Match 14.7%; Score 847; DB 2; Length 177;  
 Best Local Similarity 100.0%; Pred. No. 2.2e-52;  
 Matches 158; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MKIATVSTLPLALCLIDPAASKNEDQCHPQAFMKNGLFCPODKKFFQSLDGMFI 60

DB 1 MKIATVSTLPLALCLIDPAASKNEDQCHPQAFMKNGLFCPODKKFFQSLDGMFI 60

QY 61 NKCATCKMILKEKAKSQGRARHARAPAPATPTEINCDPFGKGRDGFICPDYEAACG 120

DB 61 NKCATCKMILKEKAKSQGRARHARAPAPATPTEINCDPFGKGRDGFICPDYEAACG 120

QY 121 TDGKTYDNRCALCAENAKTSGQIGVKSSECKSSNPQ 158

DB 121 TDGKTYDNRCALCAENAKTSGQIGVKSSECKSSNPQ 158

## RESULT 10

AAO19104  
 ID AAO19104 standard; protein; 133 AA.

XX AC AAO19104;

DT 27-NOV-2002 (first entry)

DE Human circulating Lekt1 fragment HF14448.

XX Human; circulating Lekt1 fragment; HF7072; HF7638; HF14448; haemostatic;  
 KM dermatological; antiinflammatory; gynaecological; antiasthmatic; cancer;  
 KM anti-HIV; cytostatic; pulmonary; serine protease inhibitor; AIDS;  
 KM inflammation; skin disease; asthma; emphysema.

XX OS Homo sapiens.

FN WO200266513-A2.

PD 29-AUG-2002.

PP 19-FEB-2002; 2002WO-EP001720.

PR 19-FEB-2001; 2001DE-01007997.

PA (IPFP-) IPF PHARM GMBH.

PI Walden M, Maegert H, Kreutzmann P, John H, Staendker L;

XX Forssmann W;

XX WPI; 2002-674917/72.

PT New serine protease-inhibiting peptides, useful for treating e.g.  
 inflammation or tumors, isolated from hemofiltrate, and related nucleic